Fujita, K.; Mimura, S.; Iwama, H.; Nakahara, M.; Oura, K.; Tadokoro, T.; Nomura, T.; Tani, J.; Yoneyama, H.; Morishita, A.;
et al. Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. Int. J. Mol. Sci. 2018, 19, 1940.
https://doi.org/10.3390/ijms19071940
AMA Style
Fujita K, Mimura S, Iwama H, Nakahara M, Oura K, Tadokoro T, Nomura T, Tani J, Yoneyama H, Morishita A,
et al. Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. International Journal of Molecular Sciences. 2018; 19(7):1940.
https://doi.org/10.3390/ijms19071940
Chicago/Turabian Style
Fujita, Koji, Shima Mimura, Hisakazu Iwama, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Takako Nomura, Joji Tani, Hirohito Yoneyama, Asahiro Morishita,
and et al. 2018. "Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients" International Journal of Molecular Sciences 19, no. 7: 1940.
https://doi.org/10.3390/ijms19071940
APA Style
Fujita, K., Mimura, S., Iwama, H., Nakahara, M., Oura, K., Tadokoro, T., Nomura, T., Tani, J., Yoneyama, H., Morishita, A., Oryu, M., Himoto, T., Nishitsuji, H., Shimotohno, K., Omata, M., & Masaki, T.
(2018). Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. International Journal of Molecular Sciences, 19(7), 1940.
https://doi.org/10.3390/ijms19071940